INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2016

Patents [Member]

Finite-Lived Intangible Assets [Line Items]

Intangible assets

Intangible assets, net consisted of the following at March 31, 2016 and December 31, 2015:

Intangible assets – patents		March 31, 2016	December 31, 2015
	Patent - Amlexanox (Aphthasol®)	$   2,090,000	$    2,090,000
	Patent - Amlexanox (OraDisc™ A)	6,873,080	6,873,080
	Patent - OraDisc™	73,000	73,000
	Patent - Hydrogel nanoparticle aggregate	589,858	589,858
		9,625,938	9,625,938
	Less: accumulated amortization	( 7,023,860)	(6,905,397)
	Intangible assets - patents, net	$   2,602,078	$   2,720,541

Future aggregate amortization expense for intangible assets

The future aggregate amortization expense for intangible patent assets, remaining as of March 31, 2016, is as follows:

Calendar Years		Future Amortization Expense
	2016 (Nine months)	$      357,987
	2017	475,148
	2018	475,148
	2019	475,148
	2020	476,450
	2021 & Beyond	342,197
	Total	$   2,602,078

Licensing Agreements [Member]

Finite-Lived Intangible Assets [Line Items]

Intangible assets

Licensing rights, net consisted of the following at March 31, 2016 and December 31, 2015:

Intangible assets - licensing rights		March 31, 2016	December 31, 2015
	European Union, Australia, New Zealand, Middle East (excluding Jordan and Syria), North Africa, Albania, Bosnia, Croatia, Kosovo, Macedonia, Montenegro, and Serbia.	$  3,512,506	$  3,512,506
	Less: accumulated amortization	(86,444)	(6,271)
	Intangible assets - licensing rights, net	$  3,426,062	$  3,506,235

Future aggregate amortization expense for intangible assets

The future aggregate amortization expense for intangible licensing rights assets, remaining as of March 31, 2016, is as follows:

Calendar Years		Future Amortization Expense
	2016 (Nine months)	$    244,975
	2017	325,148
	2018	325,148
	2019	325,148
	2020	325,148
	2021 & Beyond	1,880,495
	Total	$  3,426,062